Journal article · 2026 · Open access

Depletion of CCR8+ Treg cells restores dendritic cell function to drive anti-tumor immunity

Masaki Hagiwara, Azumi Ueyama, Koichi Morishita, Yamami Nakamura, Shu Aoyama, Takuro Saito, Takehiro Noda, Mamoru Uemura, Hidetoshi Eguchi, Yoji Nagira, Shimon Sakaguchi, Naganari Ohkura

Cancer Immunology Immunotherapy · Published 19 August 2026 · DOI 10.1007/s00262-026-04526-5

Open full textCite this paper

In brief

“Depletion of CCR8+ Treg cells restores dendritic cell function to drive anti-tumor immunity” is a 2026 journal article by Masaki Hagiwara and 11 co-authors, published in Cancer Immunology Immunotherapy. OpenAlex counts 0 citations as of 18 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Cancer Immunology Immunotherapy.

Citations
0
References
35
Authors
12

Abstract

CCR8-targeted regulatory T (Treg) cell depletion is a potent strategy to overcome tumor immunosuppression, yet the cellular mechanisms driving the subsequent immune response have remained unclear. This study demonstrates that anti-CCR8 antibody treatment promotes anti-tumor immunity by specifically relieving mature dendritic cells (DCs) enriched in immunoregulatory molecules (mregDCs) from Treg cell-mediated suppression. Using single-cell RNA sequencing and spatial transcriptomics in a murine colon carcinoma model, we revealed that CCR8 + Treg cell depletion induces rapid upregulation of costimulatory and activation signals in intratumoral mregDCs. The treatment also decreased mregDCs proximity to suppressive Treg cells while promoting closer interactions with both CD4 + and CD8 + effector T cells. This reactivation was also evident in tumor-draining lymph nodes, where tumor antigen-bearing migratory DCs—representing the dLN-migrating counterparts of intratumoral mregDCs—exhibited enhanced maturation, accompanied by robust priming of tumor-specific CD8 + T cells. Therapeutic efficacy was dependent on lymphocyte egress, confirming the critical role of peripheral priming. In addition, multiplex immunohistochemistry in human colorectal cancer revealed a preferential spatial association between CCR8 + Treg cells and LAMP3 + DCs (human DCs exhibiting features associated with the mregDC state), supporting the clinical relevance of this axis. Collectively, these findings indicate that anti-CCR8 therapy restores a critical antigen-presentation axis by liberating mregDCs from Treg cell-mediated suppression, thereby re-initiating the cancer-immunity cycle.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Hagiwara, M., Ueyama, A., Morishita, K., Nakamura, Y., Aoyama, S., Saito, T., Noda, T., Uemura, M., Eguchi, H., Nagira, Y., Sakaguchi, S., & Ohkura, N. (2026). Depletion of CCR8+ Treg cells restores dendritic cell function to drive anti-tumor immunity. Cancer Immunology Immunotherapy. https://doi.org/10.1007/s00262-026-04526-5

MLA 9

Hagiwara, Masaki, et al. “Depletion of CCR8+ Treg cells restores dendritic cell function to drive anti-tumor immunity.” Cancer Immunology Immunotherapy, 2026. https://doi.org/10.1007/s00262-026-04526-5.

Chicago

Hagiwara, Masaki, Azumi Ueyama, Koichi Morishita, Yamami Nakamura, Shu Aoyama, Takuro Saito, Takehiro Noda, et al. 2026. “Depletion of CCR8+ Treg cells restores dendritic cell function to drive anti-tumor immunity.” Cancer Immunology Immunotherapy. https://doi.org/10.1007/s00262-026-04526-5.

Harvard

Hagiwara, M. et al. (2026) ‘Depletion of CCR8+ Treg cells restores dendritic cell function to drive anti-tumor immunity’, Cancer Immunology Immunotherapy. doi:10.1007/s00262-026-04526-5.

IEEE

M. Hagiwara et al., “Depletion of CCR8+ Treg cells restores dendritic cell function to drive anti-tumor immunity,” Cancer Immunology Immunotherapy, 2026, doi: 10.1007/s00262-026-04526-5.

BibTeX

@article{hagiwara2026depletion,
  title     = {{Depletion of CCR8+ Treg cells restores dendritic cell function to drive anti-tumor immunity}},
  author    = {Hagiwara, Masaki and Ueyama, Azumi and Morishita, Koichi and Nakamura, Yamami and Aoyama, Shu and Saito, Takuro and Noda, Takehiro and Uemura, Mamoru and Eguchi, Hidetoshi and Nagira, Yoji and Sakaguchi, Shimon and Ohkura, Naganari},
  journal   = {Cancer Immunology Immunotherapy},
  year      = {2026},
  doi       = {10.1007/s00262-026-04526-5},
  url       = {https://doi.org/10.1007/s00262-026-04526-5}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses

  • CCR8
  • regulatory T cells
  • dendritic cells
  • tumor immunosuppression
  • antitumor immunity
  • colon cancer
  • colorectal cancer
  • tumor-draining lymph nodes

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Hagiwara, M., Ueyama, A., Morishita, K., Nakamura, Y., Aoyama, S., Saito, T., Noda, T., Uemura, M., Eguchi, H., Nagira, Y., Sakaguchi, S., & Ohkura, N. (2026). Depletion of CCR8+ Treg cells restores dendritic cell function to drive anti-tumor immunity. Cancer Immunology Immunotherapy. https://doi.org/10.1007/s00262-026-04526-5

How many times has this paper been cited?

0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Cancer Immunology Immunotherapy: sign in and open the full text from this page.

Who wrote this paper?

Masaki Hagiwara, Azumi Ueyama, Koichi Morishita, Yamami Nakamura, Shu Aoyama, Takuro Saito, Takehiro Noda, Mamoru Uemura, Hidetoshi Eguchi, Yoji Nagira, Shimon Sakaguchi, Naganari Ohkura.

What is the DOI of this paper?

10.1007/s00262-026-04526-5, permanently at https://doi.org/10.1007/s00262-026-04526-5. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.